At Asembia AXS26, Dee Chaudhary broke down how shifting US drug pricing policy is tightening payer controls and changing ...
Scaling from ultra-rare volumes to mainstream indications threatens redundancy-heavy manufacturing and logistics, forcing ...
Live from Asembia AXS26, Jessica Lovett explains what real world evidence and data matters most in making decisions around ...
PBM reform is accelerating via FTC settlements and CAA 2026, mandating data reporting, rebate pass-through in Part D, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results